No strong evidence GLP‑1s cause thyroid cancer

A warning on some of the most popular weight-loss and diabetes drugs has left many patients with the same question: if glucagon-like peptide-1 receptor agonists can help control blood sugar and body weight, do they also raise the risk of thyroid cancer? A new white paper says the answer appears to be no for the thyroid cancers most clinicians actually see. Reviewing human studies, rodent toxicology, and surgical experience, the authors concluded there is no convincing evidence that glucagon-like peptide-1 receptor agonists cause papillary, follicular, or oncocytic thyroid cancers. (cancernetwork.com) Glucagon-like peptide-1 receptor agonists are the class that includes semaglutide and tirzepatide. These drugs are now used at enormous scale for type 2 diabetes, obesity, and in some cases cardiovascular risk reduction, so even a theoretical cancer signal gets attention fast. (accessdata.fda.gov) The source of the worry is a United States Food and Drug Administration boxed warning tied to rodent studies. In those animal studies, semaglutide caused thyroid C-cell tumors, and current prescribing information says it is unknown whether that finding applies to humans. The label also says these drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (accessdata.fda.gov) That distinction matters because medullary thyroid carcinoma is not the same thing as the far more common differentiated thyroid cancers discussed in the new paper. Papillary, follicular, and oncocytic tumors arise from different thyroid cell types than the C-cells implicated in the rodent signal. (cancernetwork.com) The white paper argues that this biological difference is one reason the rodent warning should not be casually generalized to every thyroid nodule or every thyroid cancer diagnosis. According to the review, human C-cells appear to express much lower levels of glucagon-like peptide-1 receptors than rodent C-cells, and human studies have not shown a clinically meaningful rise in calcitonin, a marker tied to C-cell activity. (cancernetwork.com) The strongest support for that view comes from larger human datasets. A Scandinavian cohort study published in The BMJ used nationwide registry data from Denmark, Norway, and Sweden and found that glucagon-like peptide-1 receptor agonist use was not associated with a substantially increased risk of thyroid cancer over a mean follow-up of 3.9 years. (bmj.com) A second large analysis, published in the journal Thyroid, pooled six population-based databases from Canada, Denmark, Norway, South Korea, Sweden, and Taiwan. That multisite cohort study likewise found no evidence that glucagon-like peptide-1 receptor agonists increased thyroid cancer risk compared with dipeptidyl peptidase-4 inhibitors. (liebertpub.com) More recent work has also looked at what happens after a thyroid cancer is already present. A Journal of the Endocrine Society study published in January 2026 followed patients with low-risk papillary thyroid carcinoma undergoing active surveillance and found that glucagon-like peptide-1 receptor agonist exposure did not change tumor growth kinetics in that cohort, although the study was small and the authors called for larger studies. (academic.oup.com) None of this means the boxed warning disappears. The warning still applies to medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2, and the new paper does not claim those precautions should be ignored. What it does say is that pharmacovigilance for a rare C-cell cancer should be kept separate from day-to-day morphologic decisions about common thyroid nodules. (accessdata.fda.gov) (cancernetwork.com) That is where fine-needle aspiration comes in. Fine-needle aspiration is the standard needle biopsy used to sample thyroid nodules, and the American Thyroid Association guidelines base those biopsy decisions on clinical and ultrasound features, not on whether a patient happens to be taking a glucagon-like peptide-1 drug. (liebertpub.com) So the practical message is narrower than the headline. This paper does not create a new screening program, does not change existing fine-needle aspiration indications, and does not prove zero risk in every possible thyroid scenario. It does suggest that when a patient on semaglutide or tirzepatide is found to have a thyroid nodule, the conversation should start with the nodule’s ultrasound pattern and the patient’s actual risk factors, not with an automatic assumption that the drug caused it. (cancernetwork.com) (liebertpub.com) That may sound like a modest conclusion, but it lands in a very large patient population. As glucagon-like peptide-1 receptor agonists move from diabetes care into mainstream obesity and cardiometabolic treatment, clinicians are going to see many more patients who use these drugs and also happen to have thyroid nodules, which are common in the general population. (accessdata.fda.gov) (liebertpub.com) The white paper’s core point is that coincidence is not causation. In a population where both thyroid nodules and glucagon-like peptide-1 drug use are common, more overlap is inevitable, and the current human evidence does not show that these medicines are driving the common thyroid cancers that dominate endocrine practice. (cancernetwork.com) (bmj.com)